Redefining the management of severe asthma

WRITTEN BY

Lykke Hinsch Gylvin - Head of PRECISION, Global Medical Affairs, AstraZeneca

It’s estimated that as many as 33.9 million people worldwide are currently living with severe, uncontrolled asthma, a hugely debilitating and potentially fatal disease.1,2, Severe asthma is associated with significantly more symptoms than those experienced by people living with a mild or moderate form of asthma, meaning frequent exacerbations and significant limitations on lung function and quality of life.3

During the past decade, science has helped to advance our understanding of this disease, including its causes and management options. However, as this understanding evolves, so must the systems responsible for delivering care to ensure that patients can benefit.

It’s in this context that AstraZeneca has committed to working with global and national respiratory experts from clinical practice, patient advocacy groups and the wider stakeholder community, with the aim of accelerating patient referrals to specialists, building clinical capabilities, expanding system capacity and ultimately redefining the way in which severe asthma is currently managed.

To achieve this, we have embarked on a wide-ranging programme of engagement, named PRECISION, which has four primary objectives:

Accelerate the patient journey – Support healthcare networks to ensure timely and accurate referral of patients suspected of having severe asthma, from primary care to specialists.

Build capability –  Support improved education around the diagnosis and treatment of severe asthma.

Expand capacity – Assist existing health system infrastructures to deliver efficiencies in severe asthma care and service provision, while exploring the development of new services and new ways to meet patient demand.

Improve access – Work with advocates across the severe asthma community, building consensus and identifying current gaps that need addressing to help ensure people living with severe asthma have access to appropriate treatment and care.

Working in partnership with healthcare providers, with the clinical community and with patients, AstraZeneca aims to support a significant upshift in the systems of care that determine the daily realities of life for millions living with severe asthma around the world. We are committed to transforming the way severe asthma services are designed and delivered to reduce the burden it places on the individual, the health system and broader society.

For more information on PRECISION, contact:  Timothy Geldard (timothy.geldard@astrazeneca.com)

At AstraZeneca, we aim to transform the treatment of respiratory disease with our portfolio of inhaled and biologics medicines, along with scientific research targeting the underlying causes of the disease. Click here to find out more.

References

1.     Chung KF et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014. 43:343–73.

2.     The Global Asthma Network. The Global Asthma Report 2018. Accessed 7 September 2018. Available at: http://globalasthmareport.org/Global%20Asthma%20Report%202018.pdf

3.     Shaw DE, et al. Clinical and inflammatory characteristics of the Europea U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015. 46:1308-21

Veeva ID: Z4-12651
Date of next review: September 2020